Navigation Links
Most Cancer Treatment Studies Aren't Published, Study Finds
Date:9/15/2008

Concern Raised about 'Cancer Publication Bias'

DURHAM, N.C., Sept. 15 /PRNewswire/ -- Less than 20 percent of registered clinical trials of cancer treatment are eventually published in medical journals, according to a study published online today by the journal "The Oncologist."

(LOGO: http://www.newscom.com/cgi-bin/prnh/20080627/CLF051LOGO )

Drs. Scott Ramsey and John Scoggins of University of Washington and Fred Hutchinson Cancer Research Center, Seattle, searched the National Institutes of Health's ClinicalTrials.gov registry to identify 2,028 registered research studies of cancer treatment. Major medical journals now require that all studies considered for publication be registered in a publicly accessible database like ClinicalTrials.gov .

A subsequent search of the National Library of Medicine's PubMed database showed that just 17.6 percent of the trials were eventually published in peer-reviewed medical journals. "We find that less than 1 in 5 completed trials registered since the inception of ClinicalTrials.gov are listed in the registry or PubMed as published manuscripts," Drs. Ramsey and Scoggins write.

The publication rate was particularly low for "industry-sponsored" studies, such as those funded by pharmaceutical companies -- just 5.9 percent, compared to 59 percent for studies sponsored by collaborative research networks.

Of published studies, nearly two-thirds had "positive" results-the study treatment worked as hoped. The remaining one-third had "negative" results -- the outcome was disappointing or did not merit further consideration of the tested treatment.

This finding raises concern about "publication bias" in cancer treatment trials. The researchers suspect that the rate of negative results is much higher in the studies that have gone unpublished. Drs. Ramsey and Scoggins write, "It is likely that many unpublished studies contain important information that could influence future research and present practice policy."

There are several reasons why registered trials may not be published. Some trials may fail to meet recruitment or follow-up goals. If the trial is completed and the results are negative, researchers may feel that negative studies do little to advance scientific understanding, or to enhance their professional reputation. Sponsors may not encourage researchers to publish negative results. For their part, medical journal editors may be less enthusiastic about negative studies.

However, publication of negative studies is important for several reasons -- not only to avoid repeating negative trials, but also for what can be learned from the lack of response. "Unpublished trials may have special importance in oncology, due to the toxicity and/or expense of many therapies," the researchers add. The fact that so much cancer research goes unpublished raises concerns about the completeness of available information on present and future cancer treatments.

A pair of accompanying editorials comment on the underpublication of cancer treatment studies, and suggest some approaches to addressing the problem. Dr. James H. Doroshow of the National Cancer Institute (NCI) reports on efforts to develop a database of administrative and outcomes data for all studies performed at NCI-supported institutions.

Drs. Gregory A. Curt and Bruce A. Chabner, Senior Editor and Editor-in-Chief of "The Oncologist," echo the call for increased NCI involvement in ensuring publication of funded studies. Meanwhile, the editors of "The Oncologist" are considering publication of a new, peer-reviewed, fully searchable venue for cancer treatment studies that would otherwise go unpublished. "There is a need for a new venue for publishing all well-executed trials that fail to meet positive endpoints: 'negative' in a sense, but valuable nonetheless," Dr. Curt comments.

The article entitled "Practicing on the Tip of an Information Iceberg? Evidence of Underpublication of Registered Clinical Trials in Oncology," and the accompanying editorials, to be published in the September issue of "The Oncologist," are freely available online at:

http://www.theoncologist.com/cgi/reprint/theoncologist.2008-0133v1

(article by Drs. Ramsey and Scoggins);

http://www.theoncologist.com/cgi/reprint/theoncologist.2008-0174v1

(editorial by Drs. Curt and Chabner);

http://www.theoncologist.com/cgi/reprint/theoncologist.2008-0168v1

(commentary by Dr. Doroshow).

About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 26th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 13th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. View AlphaMed Press journals at http://www.alphamedpress.org.

Contact: Dr. Martin J. Murphy, Executive Editor: 919.402.8750, Martin.Murphy@TheOncologist.com


'/>"/>
SOURCE AlphaMed Press
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Novel Technology Breaks Through Cancer Pain
8. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
9. Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
(Date:6/23/2016)... June 23, 2016 The vast majority of ... dialysis facility.  Treatments are usually 3 times a week, ... visit, including travel time, equipment preparation and wait time. ... especially grueling for patients who are elderly and frail.  ... nursing and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many of ... beholder, according to experts who offered insights and commentary in the current issue of ... full issue, click here . , For the American Society of Clinical Oncology ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
Breaking Medicine News(10 mins):